Determination of xanomeline and active metabolite, N-desmethylxanomeline, in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
We have developed a method for the determination of xanomeline and its pharmacologically active N-desmethyl metabolite. The validated method uses hexane to extract xanomeline and its N-desmethyl metabolite from basified plasma. The hexane extract is dried, reconstituted, and analyzed using a liquid chromatographic-atmospheric pressure chemical ionization tandem mass spectrometry system. The method was developed to support phase II clinical trials and has proven to be extremely sensitive, fast, and rugged. The method has a limit of quantitation of 75 and 200 pg/ml plasma for xanomeline and the N-desmethyl metabolite, respectively. Sample analysis times were less than 3 min from one injection to the next.
Murphy
A T
AT
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Kasper
S C
SC
Gillespie
T A
TA
Delong
A F
AF
D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D018721:Muscarinic Agonists / Q000097:blood*; D011725:Pyridines / Q000097:blood*; D012015:Reference Standards; D015203:Reproducibility of Results; D013830:Thiadiazoles / Q000097:blood*
D018721:Muscarinic Agonists; C096555:N-desmethylxanomeline; D011725:Pyridines; D013830:Thiadiazoles; C075257:xanomeline